Immunocore Holdings PLC Sponsored ADR $IMCR Stock Position Reduced by Principal Financial Group Inc.

Principal Financial Group Inc. cut its position in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 9.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 411,409 shares of the company’s stock after selling 43,510 shares during the quarter. Principal Financial Group Inc.’s holdings in Immunocore were worth $14,946,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its holdings in shares of Immunocore by 51.6% during the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock worth $33,000 after purchasing an additional 311 shares during the period. Caitong International Asset Management Co. Ltd grew its position in shares of Immunocore by 4,696.3% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock valued at $41,000 after buying an additional 1,268 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in Immunocore during the second quarter worth about $42,000. Osaic Holdings Inc. lifted its holdings in Immunocore by 117.4% in the second quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock worth $97,000 after acquiring an additional 1,700 shares during the last quarter. Finally, State of Tennessee Department of Treasury acquired a new position in Immunocore in the second quarter valued at approximately $132,000. Institutional investors own 84.50% of the company’s stock.

Wall Street Analysts Forecast Growth

IMCR has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Wednesday, February 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Wells Fargo & Company began coverage on shares of Immunocore in a research report on Friday, October 31st. They set an “overweight” rating and a $60.00 price target for the company. Finally, UBS Group set a $55.00 price objective on shares of Immunocore and gave the company a “buy” rating in a research report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $60.40.

Immunocore Stock Performance

Shares of IMCR opened at $33.26 on Tuesday. Immunocore Holdings PLC Sponsored ADR has a one year low of $23.15 and a one year high of $40.71. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of -58.35 and a beta of 0.78. The company has a debt-to-equity ratio of 0.99, a current ratio of 6.00 and a quick ratio of 5.97. The company has a 50-day moving average of $34.68 and a two-hundred day moving average of $34.37.

Immunocore Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.